Bio-Rad and Diagenode partner to accelerate epigenomic research
[DENVILLE, NJ and HERCULES, Calif.] – Diagenode, Inc., a leading global provider of solutions for epigenetics research and sample preparation, and Bio-Rad Laboratories, Inc., a global leader in life science research and clinical diagnostic products, today announced a partnership in which Diagenode will offer Single-Cell ATAC-Seq (scATAC-Seq) services, featuring Bio-Rad’s Droplet Digital PCR (ddPCR) technology, to help advance epigenomics research.
Diagenode’s scATAC-Seq services leverage the combined capabilities of ddPCR technology and Diagenode’s epigenetics expertise to help researchers gain a greater understanding of the epigenome, the multitude of chemical compounds and proteins that give instructions to the genome. The scATAC-Seq services utilize Bio-Rad’s ddSEQ Single-Cell Isolator to encapsulate thousands of cell nuclei or whole cells into nanoliter-sized droplets and offer robust precision and quantification of data.
scATAC-Seq solutions enable the genome-wide study of accessible chromatin that represents regulatory regions at the single-cell level. In contrast to standard bulk ATAC-Seq, scATAC-Seq provides a way for thousands of cells to be assessed in parallel to better parse heterogeneous populations.
“We are excited to offer scientists the combination of Diagenode’s epigenetic service excellence and Bio-Rad’s industry-leading scATAC-Seq technology,” said Joe Bertelsen, Business Unit Manager at Diagenode. “This collaboration demonstrates our continued commitment to enabling advances in epigenomics research.”
“Bio-Rad is pleased to partner with Diagenode, a key player in the epigenetics market,” said Kris Simonyi, Global Marketing Manager at Bio-Rad’s Digital Biology Group. “By working together to combine our expertise, we look forward to accelerating epigenetics and gene regulation research at the single-cell level.”
To learn more about Diagenode’s scATAC-Seq services, please visit: https://www.diagenode.com/p/single-cell-atac-seq-service
